Hepatitis C virus inhibitors

Details Hepatitis C virus inhibitors Hepatitis C virus inhibitors

2006-11-07

2006-11-07

Campell, Bruce R. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Synthesis of peptides

Reexamination Certificate

active

07132504

ABSTRACT:
Compounds are disclosed having the general formula:wherein R1, R2, R3, R4, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

REFERENCES:
patent: 5633388 (1997-05-01), Diana et al.
patent: 5866684 (1999-02-01), Attwood et al.
patent: 5869253 (1999-02-01), Draper et al.
patent: 6018020 (2000-01-01), Attwood et al.
patent: 6225284 (2001-05-01), Albert et al.
patent: 6265380 (2001-07-01), Tung et al.
patent: 6268207 (2001-07-01), Bailey et al.
patent: 6323180 (2001-11-01), Llinas-Brunet et al.
patent: 6410531 (2002-06-01), Llinas-Brunet et al.
patent: 6420380 (2002-07-01), Llinas-Brunet et al.
patent: 6534523 (2003-03-01), Llinas-Brunet et al.
patent: 6642204 (2003-11-01), Llinas-Brunet et al.
patent: 6869964 (2005-03-01), Campbell et al.
patent: 6872805 (2005-03-01), Campbell et al.
patent: 6878722 (2005-04-01), Campbell et al.
patent: 6919423 (2005-07-01), Llinas-Brunet
patent: 2002/0111313 (2002-08-01), Campbell et al.
patent: 2004/0048802 (2004-03-01), Ripka et al.
patent: 2004/0077551 (2004-04-01), Campbell et al.
patent: 2005/0020503 (2005-01-01), Llinas-Brunet et al.
patent: 1162196 (2000-12-01), None
patent: WO 95/33764 (1995-12-01), None
patent: WO 97/06804 (1997-02-01), None
patent: WO 97/43310 (1997-11-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 98/46597 (1998-10-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/38888 (1999-08-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/64442 (1999-12-01), None
patent: WO 00/06529 (2000-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/13708 (2000-03-01), None
patent: WO 00/18231 (2000-04-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/85172 (2001-11-01), None
patent: WO 02/04425 (2002-01-01), None
patent: WO 02/06246 (2002-01-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 03/064416 (2003-08-01), None
patent: WO 03/064455 (2003-08-01), None
patent: WO 03/064456 (2003-08-01), None
patent: WO 03/066103 (2003-08-01), None
patent: WO 03/099274 (2003-12-01), None
patent: WO 03/099316 (2003-12-01), None
patent: WO 2004/032827 (2004-04-01), None
patent: WO 2004/043339 (2004-05-01), None
patent: WO 2005/046712 (2005-05-01), None
U.S. Appl. No. 10/992,566, filed Nov. 18, 2004, Tu et al.
U.S. Appl. No. 10/992,548, filed Nov. 18, 2004, Scola et al.
Lauer, G. M. et al., “Hepatitis C Virus Infection,” The New England Journal of Medicine, vol. 345, No. 1, pp. 41-52 (2001).
Zeuzem, S. et al., “Peginterferon Alfa-2a In Patients with Chronic Hepatitis C,” The New England Journal of Medicine, vol. 343, No. 23, pp. 1666-1672 (2000).
Poynard, T. et al., “Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus,” The Lancet, vol. 352, pp. 1426-1432 (1998).
Poupart et al., “Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease,” The Journal of Organic Chemistry, vol. 66, No. 14, pp. 4743-4751 (2001).
Steinkuhler et al., “Product Inhibition of the Hepatitis C Virus NS3 Protease,” Biochemistry, vol. 37, pp. 8899-8905 (1998).
Ingallinella et al., “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products,” Biochemistry, vol. 37, pp. 8906-8914 (1998).
Chu et al., “Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from Streptomyces sp.,” Tetrahedron Letters, vol. 37, No. 40, pp. 7229-7232 (1996).
Matsumoto et al., “3D Modeling of HCV Protease and Computer Screening of its Inhibitors,” Antiviral Research, vol. 30, No. 1, pp. A23, Abstract 19 (1996).

Affiliated with

Also associated with

Rating

Hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3630080